<?xml version='1.0' encoding='utf-8'?>
<document id="19467820"><sentence text="Biotransformation and in vitro assessment of metabolism-associated drug-drug interaction for CRx-102, a novel combination drug candidate." /><sentence text="CRx-102 is an oral synergistic combination drug which contains the cardiovascular agent, dipyridamole (DP) and a very low dose of the glucocorticoid, prednisolone (PRED)"><entity charOffset="89-101" id="DDI-PubMed.19467820.s2.e0" text="dipyridamole" /><entity charOffset="134-148" id="DDI-PubMed.19467820.s2.e1" text="glucocorticoid" /><entity charOffset="150-162" id="DDI-PubMed.19467820.s2.e2" text="prednisolone" /><entity charOffset="164-168" id="DDI-PubMed.19467820.s2.e3" text="PRED" /><pair ddi="false" e1="DDI-PubMed.19467820.s2.e0" e2="DDI-PubMed.19467820.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19467820.s2.e0" e2="DDI-PubMed.19467820.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19467820.s2.e0" e2="DDI-PubMed.19467820.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19467820.s2.e0" e2="DDI-PubMed.19467820.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19467820.s2.e1" e2="DDI-PubMed.19467820.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19467820.s2.e1" e2="DDI-PubMed.19467820.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19467820.s2.e1" e2="DDI-PubMed.19467820.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19467820.s2.e2" e2="DDI-PubMed.19467820.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19467820.s2.e2" e2="DDI-PubMed.19467820.s2.e3" /></sentence><sentence text=" CRx-102 works through a novel mechanism of action in which DP selectively amplifies the anti-inflammatory activity of PRED without replicating its side effects"><entity charOffset="119-122" id="DDI-PubMed.19467820.s3.e0" text="PRED" /></sentence><sentence text=" CRx-102 is in clinical trials for the treatment of osteoarthritis" /><sentence text=" Here we delineate the in vitro metabolism and explore the potential for a drug-drug interaction between the active agents in CRx-102" /><sentence text=" Our study using human hepatocyte suspensions showed that both DP and PRED were metabolized by CYP3A4 isozymes, resulting in the formation of diverse arrays of both oxidative and oxidative-reduced metabolites"><entity charOffset="70-73" id="DDI-PubMed.19467820.s6.e0" text="PRED" /></sentence><sentence text=" Within phase 1 biotransformation, CYP3A4 was one of the pathways responsible for the metabolism of PRED, while phase 2 biotransformation played a significant role in the metabolism of DP"><entity charOffset="100-103" id="DDI-PubMed.19467820.s7.e0" text="PRED" /></sentence><sentence text=" Glucuronidation of DP was substantial and was catalyzed by many UGT members, specifically those in the UGT1A subfamily" /><sentence text=" Based on the tandem mass (MS/MS) product ion spectra (PIS) acquired, the major metabolites of both agents, namely, monooxygenated, mono-N-deethanolaminated, dehydrogenated and O-glucuronidated metabolites of DP and the monooxygenated (e" /><sentence text="g" /><sentence text=", 6-hydroxyl), dehydrogenated (prednisone) and reduced (20-hydroxyl) metabolites of PRED, were identified and elucidated"><entity charOffset="31-41" id="DDI-PubMed.19467820.s11.e0" text="prednisone" /><entity charOffset="84-93" id="DDI-PubMed.19467820.s11.e1" text="PRED" /><pair ddi="false" e1="DDI-PubMed.19467820.s11.e0" e2="DDI-PubMed.19467820.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19467820.s11.e0" e2="DDI-PubMed.19467820.s11.e1" /></sentence><sentence text=" The affinities for DP biotransformation, including CYP3A4-mediated oxidative pathways and UGT-mediated O-glucuronidation, appeared high (K(m)&lt;10 microM), as compared with the modest affinities of PRED biotransformation catalyzed by CYP3A4 (K(m) approximately 40-170 microM)"><entity charOffset="197-200" id="DDI-PubMed.19467820.s12.e0" text="PRED" /></sentence><sentence text=" DP, but not PRED, exerted a minimal inhibitory effect on the drug-metabolizing CYP isoforms, including CYP3A4, which was determined using a panel of CYP isoform-preferred substrate activities in pooled human liver microsomal (HLM) preparations and microsomal preparations containing the recombinant enzymes (K(i) approximately 2-12 microM)"><entity charOffset="13-16" id="DDI-PubMed.19467820.s13.e0" text="PRED" /></sentence><sentence text=" Using the DP maximal plasma concentration (C(max)) observed in the clinic and a predictive mathematical model for metabolism-associated drug-drug interaction (DDI), we have demonstrated that there is little likelihood of a pharmacokinetic interaction between the two active agents in CRx-102" /><sentence text="" /></document>